What laboratory tests and hormone replacement therapy (Hormone Replacement Therapy (HRT)) are recommended for a perimenopausal woman suspected of being in menopause?

Laboratory Testing for Menopause

When Laboratory Testing is NOT Required

For women aged 60 years or older, no laboratory testing is needed to diagnose menopause—age alone is sufficient for clinical diagnosis. 1

When Laboratory Testing IS Required

Women Under Age 60 with Amenorrhea

For women under 60 years with 12 months of amenorrhea, measure both FSH and estradiol levels to confirm postmenopausal status: 2, 1

• FSH should be in the postmenopausal range (typically >30-40 IU/L, though exact cutoffs vary by laboratory)
• Estradiol should be low (<50 pg/mL) 1
• The combination of elevated FSH and low estradiol provides stronger diagnostic certainty than either marker alone 1

Special Populations Requiring Different Approaches

Women on Tamoxifen or Toremifene (age <60):

• FSH alone is unreliable in this population 2, 1
• Require both FSH and plasma estradiol in postmenopausal ranges for diagnosis 2, 1

Women with Chemotherapy-Induced Amenorrhea:

• FSH is NOT a reliable marker of menopausal status 2, 1
• Serial estradiol measurements are more useful to determine return of ovarian function 1
• Amenorrhea after chemotherapy does not confirm menopause, as ovarian function may resume despite anovulation 2

Women on GnRH Agonists/Antagonists:

• It is not possible to assign menopausal status while receiving these medications 2, 1
• If definitive status determination is required, oophorectomy or serial hormone measurements after stopping medication are needed 1

Clinical Algorithm for Laboratory Testing

1. Confirm 12 months of amenorrhea before ordering any tests (in women under 60) 1

2. For women with oligomenorrhea (not complete amenorrhea), measure FSH and estradiol during the early follicular phase (days 2-5 of cycle) 1

3. Order FSH and estradiol together, not FSH alone, using local laboratory definitions of postmenopausal ranges 1

4. For women on endocrine therapy or with chemotherapy history, consider serial measurements rather than single values and monitor for clinical symptoms suggesting persistent ovarian function 1

5. If results are indeterminate, repeat measurements at least 4 weeks apart 1

---

Hormone Replacement Therapy (HRT) Recommendations

Primary Indication: Symptom Management, NOT Disease Prevention

HRT should be initiated for management of menopausal symptoms (vasomotor symptoms, genitourinary symptoms) at the time symptoms begin, NOT for routine prevention of chronic conditions like osteoporosis or cardiovascular disease. 3 The USPSTF gives a Grade D recommendation (recommends against) using HRT solely for chronic disease prevention. 3

Timing and Age Considerations

The most favorable benefit-risk profile exists for women under 60 years of age OR within 10 years of menopause onset. 3

For Women Under 60 or Within 10 Years of Menopause:

• HRT can be initiated for moderate to severe vasomotor or genitourinary symptoms 3
• The absolute risks are modest and generally outweighed by symptom relief benefits 3

For Women Over 60 or More Than 10 Years Past Menopause:

• Do NOT initiate HRT 3
• If already on HRT at age 65, reassess necessity and attempt discontinuation 3
• If continuation is deemed essential, use the absolute lowest effective dose 3

For Women with Premature Ovarian Insufficiency (POI):

• Initiate HRT immediately at diagnosis to prevent long-term cardiovascular, bone, and cognitive consequences 3
• Continue until at least age 51 (average age of natural menopause), then reassess 3

Choosing the Appropriate HRT Regimen

For Women WITH an Intact Uterus:

First-line regimen: Transdermal estradiol 50 μg patch (applied twice weekly) PLUS micronized progesterone 200 mg orally at bedtime. 3

• Progestogen is MANDATORY to prevent endometrial cancer—unopposed estrogen increases endometrial cancer risk 10- to 30-fold 3
• Transdermal route is preferred over oral because it bypasses hepatic first-pass metabolism, reducing cardiovascular and thromboembolic risks 3
• Micronized progesterone is preferred over medroxyprogesterone acetate (MPA) due to lower rates of venous thromboembolism and breast cancer risk 3

Alternative progestogen options if micronized progesterone is unavailable: 3

• Medroxyprogesterone acetate 10 mg daily for 12-14 days per month (sequential) or 2.5 mg daily (continuous)
• Dydrogesterone 10 mg daily for 12-14 days per month
• Levonorgestrel-releasing IUS (52 mg) for local endometrial protection

For Women WITHOUT a Uterus (Post-Hysterectomy):

Estrogen-alone therapy: Transdermal estradiol 50 μg patch (applied twice weekly). 3

• No progestogen is needed since there is no endometrium to protect 3
• Estrogen-alone therapy shows NO increased breast cancer risk and may even be protective (RR 0.80) 3

Absolute Contraindications to HRT

Do NOT prescribe HRT if any of the following are present: 3

• History of breast cancer or other hormone-sensitive cancers
• Active or history of venous thromboembolism or pulmonary embolism
• Active or history of stroke
• History of coronary heart disease or myocardial infarction
• Active liver disease
• Antiphospholipid syndrome or positive antiphospholipid antibodies
• Thrombophilic disorders
• Smoking in women over age 35 (relative contraindication—prescribe with extreme caution) 3

Risk-Benefit Data for Informed Consent

For every 10,000 women taking combined estrogen-progestin for 1 year: 3

Risks:

• 8 additional invasive breast cancers
• 8 additional strokes
• 8 additional pulmonary emboli
• 7 additional coronary heart disease events

Benefits:

• 75% reduction in vasomotor symptom frequency
• 6 fewer colorectal cancers
• 5 fewer hip fractures

Duration of HRT

Use the lowest effective dose for the shortest duration necessary to control symptoms. 3

• Reassess necessity annually 3
• Breast cancer risk does not appear until after 4-5 years of combined therapy, but stroke and VTE risks emerge within the first 1-2 years 3
• At age 65, reassess and attempt discontinuation 3
• No routine laboratory monitoring (FSH, estradiol levels) is required—management is symptom-based 3

Critical Pitfalls to Avoid

• Never prescribe estrogen-alone to women with an intact uterus—this dramatically increases endometrial cancer risk 3
• Never initiate HRT solely for osteoporosis or cardiovascular disease prevention in asymptomatic women 3
• Never use custom compounded bioidentical hormones or pellets—lack of safety and efficacy data 3
• Do not initiate HRT in women over 60 or more than 10 years past menopause 3
• Do not assume FSH alone is sufficient for diagnosis—always measure estradiol concurrently in women under 60 1